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Abstract
Tuberculosis is the deadliest infection of our time. In contrast, about 11,000 people died of Ebola between 2014
and 2016. Despite this manifest difference in mortality, there is now a vaccine licensed in the United States and by
the European Medicines Agency, with up to 100% efficacy against Ebola. The developments that led to the trialing
of the Ebola vaccine were historic and unprecedented. The single licensed TB vaccine (BCG) has limited efficacy.
There is a dire need for a more efficacious TB vaccine. To deploy such vaccines, trials are needed in sites that
combine high disease incidence and research infrastructure. We describe our twelve-year experience building a TB
vaccine trial site in contrast to the process in the recent Ebola outbreak. There are additional differences. Relative to
the Ebola pipeline, TB vaccines have fewer trials and a paucity of government and industry led trials. While
pathogens have varying levels of difficulty in the development of new vaccine candidates, there yet appears to be
greater interest in funding and coordinating Ebola interventions. TB is a global threat that requires similar concerted
effort for elimination.
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Background
Tuberculosis is a blight to the technological advances of
the twenty-first century. A global blueprint to combat it
has been outlined in the end TB Strategy [1]. New drugs,
diagnostics, and vaccines are in development with the
goal of elimination. To demonstrate efficacy and for ex-
ternal validity, trial sites in endemic areas are needed to
advance the various candidates through phase III licen-
sure trials. Although there are more than 22 high burden
countries (Global TB Report, 2017), vaccine trials occur
in only a handful of these, due to inadequate clinical tri-
als capacity. These challenges hinder advancement of TB
vaccine candidates.
From 2014 to 2016, there was an outbreak of the
Ebola virus in West Africa. Outbreaks had been docu-
mented periodically from 1976, with case fatalities of
90%. However, in the recent outbreak, the risk of
widespread contagion from global travel and its po-
tential for bioterrorism, prompted strong responses.
In a highly entropic environment, 13 prophylactic
vaccines were in clinical studies with at least 40%
evaluated on the African continent between 2014 and
2015 [2]. This demonstrated that under sufficient
threat, the global community can mobilize resources
and overcome adverse circumstances. Determining
vaccine efficacy during an unpredictable outbreak, in
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low resourced settings for an acutely lethal disease is
singularly difficult. ‘However, there now exists a li-
censed vaccine which demonstrated up to 100% effi-
cacy’ [2].
In light of these unusual events, we compare the TB
and Ebola vaccine development in two ways. Firstly, we
chronologically narrate our experience and learning in
building a TB vaccine trial site from the ground up.
Thereafter, we compare this with the site set-up process
for Ebola vaccine trials. Finally, we review the number of
clinical vaccine trials for both diseases, by phase and
funding, from 2014 when the Ebola outbreak began and
Phase I trials were initiated. This review incorporates
our unique site experiences in relation to current and fu-
ture TB vaccine trial sites and places our perspectives on
TB vaccine development in the context of the Ebola
outbreak.
TB vaccine trial site development
Study area and study population
Our reflections are based on studies conducted from
2007 to 2019 at a site in Siaya county, Western
Kenya (Fig. 1). The area is rural, 400 km west of the
capital Nairobi. The population mostly comprises
peasant farmers. There is a high but declining preva-
lence of TB, HIV and malaria [3]. Part of the study
area was under health and demographic surveillance
system (HDSS), tracking births, deaths, and migra-
tions [3].
Site history and development
In 2007, we, alongside other collaborators in Mozambique,
South Africa and Uganda received an European and
Developing Countries Clinical Trials’ Partnership (EDCTP)
grant to create scientific and infrastructure capacity neces-
sary for conduct of TB vaccine trials, also for site to site
skills transfer.
Two epidemiological TB studies in adolescents and in-
fants were conceived. At the time, there was little re-
search infrastructure. A collaboration with the then
Siaya Hospital was set up. Additional training for nurses
on TST administration and reading, collection of in-
duced sputa and gastric aspirates was provided by a
team from a sister site at the South Africa Tuberculosis
Vaccine Initiative. Study staff were extensively trained in
collaboration with the Vienna School of Clinical Re-
search on (among others) biostatistics, research
methods, ethics, Good Clinical Practice (GCP), and trial
site management. Also, several site staff received concur-
rent sponsorship for MSc’s and PhD’s.
Tuberculosis studies
We describe five TB studies conducted serially at our
site and the lessons learnt in each.
Adolescent cohort study (ACS)
The ACS began in 2007, with the objective of recruiting
adolescents to establish the optimal way to access them
in the study area and determine TB prevalence and inci-
dence in preparation for TB vaccine trials. A mobile field
Fig. 1 Study area. KEMRI/CDC: Kenya Medical Research Institute/Centers for Disease Control. HDSS: Health and Demographic Surveillance System
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site (MFS) was used to enroll adolescents. (Supplemen-
tary Figure 5-Mobile Field Site). The MFS was a collec-
tion of tents, a mobile radiography unit and mobile
generator pitched in a grassy open field in a school,
church compound or other open public arena. Potential
MFS sites were identified by study staff, and the site
assembled every week. The tents housed study staff,
parents and adolescents who moved serially from
consenting, TB symptom screening, TST administra-
tion or reading, to chest radiography and then to
dispatch. Data entry was on Personal Digital Assis-
tants and laptops, using a local area network powered
by the mobile generator. Upon exhausting all poten-
tials at that catchment area, the site would demobilize
and set up in a contiguous site and the process would
start over again. Follow-up visits were conducted in
similar fashion, from site to site. The challenges of
operating in an open field were particularly apparent
during the rainy seasons. The site would get flooded
or barely accessible, disrupting study processes. In
that case it would be disassembled and relocated. A
total of 5004 adolescents were recruited on target
over 12 months and 83% retained [4]. Most of the
study team rolled over into the infant study.
Infant cohort study (ICS)
Pediatric TB estimates from program data were not age-
disaggregated, masking the disproportionate affliction of
young infants with TB. In 2008, the thinking of the TB
vaccine community leaned heavily towards infants as a
key efficacy target population [5]. Therefore, the ICS
was conceived to provide estimates of TB incidence
using comprehensive diagnostic methods [5], and to
demonstrate capacity to deliver BCG within 96 h of
birth. This was to anticipate the administration of BCG
replacement candidate vaccines.
At the time, it was reported that 80% of mothers
delivered at home, with the help of a traditional birth
attendant (TBA). We engaged TBAs to assist in noti-
fying births to the study staff. The recruitment coord-
inator would then dispatch a nurse on a motorbike to
perform enrolment procedures. Thereafter, a nurse
would deliver BCG to enrolled infants. The median
age of enrollees was 10 days, therefore in many cases
it was not possible to deliver BCG within 96 h of
birth due to late notifications and problems locating
mothers who were highly mobile in the study area.
This was accentuated when due to insufficient
notifications, the study area was extended to Boro, a
nearby sub-county, which was not under the HDSS.
In addition, the terrain was frequently challenging.
Nurses were inexperienced motorbike riders and pre-
dominantly female. There were several falls that injured
their morale more than anything. Nevertheless, the team
rallied, and 2900 infants were enrolled on target within
12months.
Fortunately, the number of home births in the study
area continued to decline. By 2011, at least 40% occurred
at health facilities [6]. Future trials of BCG replacement
vaccine trials will therefore enroll infants at health
facilities.
The ICS operated out of two tents in a grassy field of
the Siaya Hospital, seeing scheduled and unscheduled
visitors. The hospital allocated a store in the pediatric
ward for creation of a negative pressure room for spe-
cialized sputum collection procedures. We renovated a
defunct, dilapidated amenity wing designed for private
patients, and converted it into a case verification ward
for overnight admissions for TB investigation
procedures.
The existing hodgepodge of facilities did not meet trial
requirements, as there was no GCP compliant pharmacy,
archival facilities, or laboratories. Therefore, in 2009,
construction of a state-of-the-art research annex (Sup-
plementary Figure 4-Siaya Clinical Research Annex) with
all the requisite infrastructure at the hospital grounds
began, funded by several partners. It was completed in
2012 and auspiciously launched.
The study also created a previously non-existent cap-
acity to diagnose pediatric TB using induced sputa and
gastric aspirates as well as structured chest radiograph
review. Staff training for the latter two procedures were
provided by a sister site at the South African Tubercu-
losis Vaccine Initiative.
There were thousands of ancillary care visits that con-
tributed the largest number of presumptive TB cases,
given the non-specific presentation of TB in infants.
Aeras-402 (Nochak)
The first TB vaccine trial at the site followed closely on the
heels of the ICS. It was a phase IIb trial of the candidate
vaccine AERAS 402 in healthy, HIV uninfected, BCG vacci-
nated infants [7]. The site was the first to be initiated into
the trial in 2010. The study team was now proficient in re-
cruitment of infants and requisite community links had
been forged. There was widespread enthusiasm for study
participation due to intense community mobilization by site
staff. Locals had branded the study ‘NoChaK’ (Nonro mar
Chanjo mar Kahera), translated ‘a new TB vaccine’ in Luo,
the local language. (Supplementary Figure 2-Community
Engagement).
Disappointment ensued when there was an inordinate
number of screen failures due to abnormal biochemis-
tries, particularly elevated total bilirubin in infants who
were in every other sense healthy. To determine eligibil-
ity, the National Institutes of Health (NIH) reference
ranges were used, which, in hindsight, were clearly de-
rived from a distinct population. It would have been
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unethical to continue screening, and therefore enrol-
ment was paused to investigate the issue. To exclude in-
valid laboratory results, the local laboratory that was also
being used for the RTS,S malaria vaccine trial [8], was
scrutinized to determine the reproducibility and repeat-
ability of affected parameters, as well as External Quality
Assurance (EQA) program results. The laboratory
cleared. We found no antecedent literature describing
what we were observing. Following wide consultations,
we developed a new set of reference ranges. This allowed
the study to proceed with enrolment. The area was hy-
perendemic for malaria and that was considered the
prime reason for the elevations in healthy infants. Years
later, two publications emerged on the subject, but for
an adult population proximal to the study area, which
mirrored our observations [9, 10].
There were significant problems with collection and
processing of Peripheral Blood Mononuclear Cells
(PBMCs). The cells needed to be separated and frozen
within 4 h of collection. The study site was about 80 km
away (about 1.5-h drive) from the immunology labora-
tory, with predictable inaccessibility in wet weather. The
process of separation took at least two hours. In
addition, eight ml of blood were collected in several tall
vials. Like many African communities, there were strong
sensitivities to blood sampling, despite our best efforts
to explain that the relative blood volumes sampled
would not adversely impact the babies given their age
and weight. Furthermore, as infants were significantly
dark skinned and healthy, if more than one attempt was
needed to collect these samples, parents would get dis-
tressed and the time taken also derailed the tight separ-
ation timelines. In response, tight orchestration of the
visits with PBMC collection was done. An experienced
phlebotomist, efficient in cutting down the collection
time was added to the team. Technicians were alerted
once the sample left and were on stand-by ready to im-
mediately begin to process the samples.
Unfortunately, the laboratory team had no prior im-
munology experience. They failed proficiency testing,
some on more than one occasion and this skill was
only gradually acquired. In addition, on one occasion
the dry ice shipper containing EQA samples arrived
at the destination laboratory dry, compromising cell
viability. The laboratory teams were retrained, and
this capacity was then available for the future trial
among adults.
The stability of AERAS 402 vaccine at 2–8 degrees
was short-lived. It was stored at − 80 °C in a research
pharmacy in Kisumu (Supplementary Figure 3-Logistics).
Twenty-four hours prior to dosing, it would be trans-
ferred from the freezer to the refrigerator and could
keep for only 6 weeks. There were frequent power out-
ages at the clinic, therefore it was not possible to safely
keep vaccine on site. Therefore, an alternative thaw
protocol was used. Vials would be removed from the
freezer, thawed at room temperature for one to two
hours, and then shipped to site under rigorous
temperature monitoring. After review of potential partic-
ipants, the study doctor would call up the vaccine from
the central pharmacy, and vaccinations would happen
upon arrival two hours later. As there were mandatory
post-vaccination observation procedures, many mothers
were dropped off at their homes late in the night, which
created friction in families. Mothers agreed to assemble
for early pick-ups on days of randomization, and thus
there was only one vaccine run to Kisumu.
TB018 (M72)
The second vaccine trial in this site was a phase IIb trial
of another candidate vaccine M72/AS01E against pla-
cebo [11]. The site’s successful experience with the MFS
made it a compelling recruitment strategy for this trial.
A total of 538 individuals were randomized over a period
of 8 months. The laboratory was now experienced in
handling immunology samples and there were few
hitches.
VPM1002
In 2018, towards the end of the M72 study, our site was
selected to participate in a phase III trial of VPM1002, a
TB vaccine candidate against BCG among infants. The
cumulative site experience in immunology, infant re-
cruitment, TB case detection, and adverse event surveil-
lance continues to be applied for this trial. Recruitment
is expected to end by the second quarter of 2022, with a
minimum follow-up time of 12 months.
Lessons from site development
Importance of epidemiological studies
The epidemiological studies seriously enhanced our cap-
acity to perform future trials with increasing ease and
excellence. Increasingly, funding pressures have con-
strained the space for epidemiological studies, as they
offer knowledge with no prospects of ‘return on invest-
ment’. The placebo arm is sometimes viewed as the epi-
demiological understudy. The trial population, however,
is usually a selected sub-group that are healthier, HIV
uninfected, and probably more accessible to the research
team based on their different health seeking behavior.
Being subjects of intense health monitoring, they likely
have lower risks of TB acquisition. The placebo arm
therefore provides little context for the interpretation of
trial results, which are rarely linear or straight-forward.
Therefore, epidemiological studies should not be consid-
ered optional.
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Biobanking inclusivity
Health research capacity building is not without power
relations [12]. Biobanking is a part of virtually every TB
vaccine trial. However, once samples are shipped to cen-
tral laboratories in Western Europe or North America,
research teams have no say in the deployment of those
assays, even while they made great efforts to collect
them. It is intellectually impoverishing; research teams
having the derogatory epithet ‘sample traffickers’. In
hindsight, a biobanking capacity-building component
should have been included in the initial studies, creating
the legal and scientific framework to ensure
democratization and inclusivity.
Ebola site development
Having reflected on the development of our TB vaccine
site, we turn our attention to the development of sites
during the Ebola outbreak. As Ebola mortality increased
during the 2014 outbreak, promising vaccine candidates
stuck in preclinical phases for years [2] due to lack of
funding or interest, were fast-tracked into human trials
[13–15]. Clinical trial protocols were ready within weeks.
Ethical and regulatory reviews were turned around in 2
weeks [16]. Preliminary efficacy results were availed in
unprecedented time for rapid decision making [17]. The
transition to Phase II/III studies was unmatched, at 8
months, instead of ordinarily one to 3 years [18, 19] after
initiation of the phase I study [2].
To have any hope of demonstrating efficacy, the stud-
ies needed to be initiated before the unpredictable out-
break ended. However, most study areas were
unmapped, and lacked electricity and basic amenities. In
some places years of civil war had destroyed health in-
frastructure. Scores of health workers had lost their lives
in the outbreak [20], and those who remained were in-
volved in emergency response to victims. Thus, local
trained research teams were virtually non-existent [21],
as were any ‘clinical research sites’ [16, 21]. Despite all
this, the necessary facilities were put up on the go, and
teams adapted other trial aspects to the less ideal real-
ities in the field [19].
The World Health Organization (WHO) was pivotal
in overcoming all the challenges by fostering interactions
with scientific, ethics, regulatory, industry and funder
groups from every continent [17].
Evidently, with high stakes, absent infrastructure or re-
search teams are not obstacles to trial implementation
or success. Further, most countries with high TB burden
have significantly fewer barriers to trial set-up compared
to those setting up Ebola trials.
Lessons for TB vaccine trials from Ebola
The trialing and availability of a highly efficacious vac-
cine for Ebola in an extraordinarily short amount of
time, led us to compare the vaccine pipelines, the rela-
tive numbers of clinical trials, vaccination strategies as
well as the theoretical probability of success for each
disease.
Vaccine trial pipeline
Table 1: Ebola versus TB vaccine candidate pipeline
from 2014 (WHO Vaccine Pipeline Tracker (https://
www.who.int/immunization/research/vaccine_pipeline_
tracker_spreadsheet/en/) accessed 12 Oct 2019). (Some
trials have more than one sponsor).
We assume that a disease’s vaccine pipeline is a proxy
for intensity of research and that a diverse, robust pipe-
line is more likely to produce a candidate that shows ef-
ficacy [21, 22]. The TB vaccine pipeline has fewer
studies than does Ebola and there is also under-
representation of government and industry sponsored
trials. The economic cost of each epidemic makes a
compelling case for both industry and government in-
volvement. Economic losses, in West Africa and globally,
were estimated at USD 18 billion as a result of the
2014–2016 outbreak [23]. The annual societal cost alone
of TB is USD 19 billion [1]. The WHO has supported
TB vaccine initiatives [22], but the Ebola outbreak
showed us that much more is possible, especially in solv-
ing macro-level problems and mobilizing resources,
probably even in sponsoring trials [16].
As of September 2019, there were only eight preclin-
ical vaccine candidates for TB (www.tbvi.eu/what-we-
do/pipeline-of-vaccines) accessed 30 September 2019. A
main reason for this, other than minimal public interest
in accelerating a new TB vaccine, is funding restrictions
[24]. As a result, stage-gate criteria have been developed
to constrict the movement of candidates from one phase
Table 1 shows the trials initiated for Ebola versus TB vaccines in
the last 5 years when Ebola vaccine trials entered the clinical
phase
Ebola vaccine trials TB vaccine trials
Total clinical trials 60 30
Phase 1 34 13
Phase 2 16 10
Phase 3 8 6
Phase 4 2 1
Sponsors
Industry 21 7
Non-profit 0 6
Academia 14 16
Government sponsors 17 3
a. Russia (MoH) 3 1
b. China (Jiangsu Province) 3 0
c. USA (CDC, NIAID) 11 2
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to the next, with the idea of advancing only the most
promising candidates, defined largely by available im-
munogenicity, efficacy, and safety data [21, 22]. At
most of the early stage gate points, particularly pre-
clinical to clinical, and Phase I to Phase IIb, the can-
didate has the least possible ‘value chain’ defined as
the accumulation of value due to demonstrated safety
or efficacy or both [23].
Furthermore, immunogenicity criteria [22] that quan-
tify vaccine-induced immune responses may not repre-
sent protection against disease. These criteria may be
flawed, leading to false negatives or positives. While
clearly some criteria are needed to advance candidates,
the way out seems to be through actual clinical efficacy
studies.
Probability of success of a vaccine trial
The difficulty in vaccine design differs from pathogen to
pathogen. The average vaccine requires a clinical devel-
opment timeline of 10.7 years and has a market entry
probability of 6% [23]. Table 2 shows selected require-
ments thought to impact the feasibility of accelerated
vaccine development. Mycobacterium tuberculosis is
considerably more complex, with great capacity to evade
host immunity [25]. Also, animal models that closely
mimic human disease are better for Ebola virus than TB.
Hence a new TB vaccine could be termed ‘unprece-
dented’ and the odds of success are pegged considerably
lower than for most other diseases [24]. These estimates
are valid but are based on past experience with limited
government and industry involvement and a minimal
global effort.
Vaccination strategies and phase II/III trial sites
Ring vaccination in the Guinea Ebola vaccine trial pro-
vided preliminary efficacy data in a highly dynamic out-
break [2]. The most at risk persons were singled out for
vaccination, as opposed to vaccinating an entire
community.
There are irrefutable data on asymmetries of TB risk
(‘TB hotspots’) [37, 38] based on residence (urban vs.
rural) [39, 40], certain geographic locations including
prison [41] and mines [42], social class interactions [43],
and age [44, 45]. Such epidemiological data have not
been applied in selecting trial populations for phase IIb-
IV trials, yet they would critically minimize sample sizes,
guide site selection and provide rapid answers as to a
vaccine’s efficacy. This was one of the pathways explored
in the Ebola outbreak.
Conclusions
We have described our incremental 12-year process of
site development, in contrast to an acute, chaotic and
very productive process in the Ebola virus outbreak.
Since the ACS in 2007, about a dozen other phase II and
III trials have been conducted at our site. Subsequent
studies have found better infrastructure, more highly ex-
perienced teams, and the complexity of protocols imple-
mented at the site has also increased. Nevertheless, the
end goal is a new efficacious TB vaccine brought to bear
on the epidemic.
TB unlike Ebola has a lower case fatality, slower epi-
demic, and lower potential for bioterrorism. But its total
mortality is hundreds to thousands of times higher. It is
our view that developing a new TB vaccine will also re-
quire centralized coordination of efforts.
The TB vaccine pipeline is plagued not simply by
funding limitations, but by an inadequate number of
‘hands on deck’. The Ebola crisis calls for a sense of ur-
gency towards the TB epidemic, and for a narrowed
focus. For example, the lack of knowledge of correlates
of protection has not prevented the advancement of a
new malaria, polio [46], or Ebola vaccine [47, 48], nei-
ther the eradication of small pox [49]. Funds can be pri-
oritized for pre-clinical development and field testing of
candidates in order to stop the scourge, else the goal of
TB elimination will remain elusive [1]. Given an Ebola
vaccine was evaluated and licensed under extreme con-
ditions, it is a rallying call for the TB vaccine community
to champion the cause.
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Table 2 Feasibility of accelerated vaccine development
(Institute of Medicine (US) Committee on Issues and Priorities
for New Vaccine Development [26]
Requirement Ebola
Virus
Tuberculosis
knowledge of clinical signs and symptoms
of the disease to allow differentiation from
similar syndromes
+ ++
Knowledge of pathogen characteristics: strains,
serotypes, infectivity, virulence, antigenicity,
immunogens
++ [27] ++ [28, 29]
Strains & Serotypes
Infectivity and Virulence
Antigenicity
Immunogens
Ability to cultivate pathogen + [30] ++
Identified non-human models of infection,
closely mimicking human disease
+++
[31]
++ [32]
Knowledge of human immune response to
the pathogen (duration, type of response)
+ [33] + [34]
Definition of the target population + [35] ++ [36]
Kaguthi et al. BMC Public Health          (2020) 20:999 Page 6 of 8
Additional file 3: Figure S4. Siaya Clinical Research Annex.
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